Alliancebernstein L.P. Sells 3,500 Shares of Bioventus Inc. (NYSE:BVS)

Alliancebernstein L.P. decreased its holdings in Bioventus Inc. (NYSE:BVS) by 21.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 13,170 shares of the company’s stock after selling 3,500 shares during the period. Alliancebernstein L.P.’s holdings in Bioventus were worth $138,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of BVS. Plato Investment Management Ltd acquired a new stake in Bioventus in the fourth quarter valued at approximately $38,000. KLP Kapitalforvaltning AS bought a new position in shares of Bioventus in the 4th quarter valued at $75,000. Quantbot Technologies LP acquired a new stake in shares of Bioventus during the 4th quarter valued at $103,000. Arizona State Retirement System bought a new stake in Bioventus during the 4th quarter worth $109,000. Finally, HighTower Advisors LLC increased its holdings in Bioventus by 11.3% in the 4th quarter. HighTower Advisors LLC now owns 13,617 shares of the company’s stock worth $143,000 after purchasing an additional 1,380 shares in the last quarter. Institutional investors and hedge funds own 62.94% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group reissued a “buy” rating and set a $15.00 price target on shares of Bioventus in a research note on Monday, March 17th.

Insider Activity at Bioventus

In other news, SVP Anthony D’adamio sold 4,380 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total value of $44,632.20. Following the transaction, the senior vice president now directly owns 118,178 shares of the company’s stock, valued at $1,204,233.82. The trade was a 3.57 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Mark Leonard Singleton sold 6,498 shares of Bioventus stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total value of $66,214.62. Following the completion of the sale, the chief financial officer now owns 118,817 shares of the company’s stock, valued at approximately $1,210,745.23. The trade was a 5.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 24,208 shares of company stock worth $226,138 over the last ninety days. Insiders own 32.90% of the company’s stock.

Bioventus Stock Down 0.1 %

Shares of NYSE:BVS opened at $7.49 on Wednesday. The firm has a market cap of $613.76 million, a P/E ratio of -12.28 and a beta of 0.92. Bioventus Inc. has a 12-month low of $3.90 and a 12-month high of $14.38. The business has a fifty day simple moving average of $9.18 and a 200 day simple moving average of $10.54. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.